HLA haplotype sharing by siblings with rheumatoid arthritis: evidence for genetic heterogeneity

DAVID M GRENNAN, PAUL A SANDERS, PHILIP A DYER, AND RODNEY HARRIS

From the University of Manchester Rheumatic Diseases Centre, Hope Hospital, Salford M6 8HD; and the University Department of Medical Genetics, St Mary's Hospital, Manchester

SUMMARY  HLA haplotype sharing was studied in 35 sibships in which there were two or more members with rheumatoid arthritis (RA). Haplotype sharing by RA siblings was random in 15 sibships which included members with clinical or immunological features of autoimmune thyroid disease. In the remaining 20 'non-thyroid' sibships the frequencies of RA siblings sharing 0, 1, or 2 haplotypes were 0.04, 0.48, and 0.48 respectively (p=0.006). 67% of RA probands in the 'thyroid' families and 90% in the other families were HLA-DR4 positive. It is suggested that there is genetic heterogeneity in the pathogenesis of RA with at least two independent genes within the major histocompatibility complex (MHC) predisposing to RA. One gene is in linkage disequilibrium with HLA-DR4, while results of comparison of DR antigen frequencies in DR4 negative RA and control groups suggest that the other is in linkage disequilibrium with HLA-DR1 and 3. In the thyroid disease families both genes are frequently present and as either may predispose to arthritis, HLA haplotype sharing is random. The frequencies of HLA haplotype sharing in the 'non-thyroid' families suggest that there is a dominant susceptibility gene in linkage disequilibrium with HLA-DR4, whose frequency is 5% and penetrance about 20%.

Key words: autoimmune thyroid disease, gene frequency, dominant gene.

Rheumatoid arthritis (RA) is thought to be caused by an interaction between a polygenic disease susceptibility and unknown environmental factors.1 There is a well documented association between RA and HLA-DR4 in most populations studied,2 suggesting that a gene or genes within the MHC may be responsible for at least part of this genetic susceptibility. The presence of DR4 negative RA patients could represent linkage disequilibrium between DR4 and a single RA susceptibility gene within the MHC or genetic heterogeneity with different susceptibility genes within the MHC for DR4 positive and negative RA. We have suggested previously that genes for autoimmune thyroid disease may predispose to RA independently of DR4.3 In the present study we have compared HLA haplotype sharing by DR4 positive and negative RA probands with their affected sibs in sibships which either do or do not have individuals with autoimmune thyroid disease. If there is a single RA susceptibility gene within the MHC, then HLA haplotype sharing by RA sibs should be greater than random and not affected by either DR status of the proband or by the presence or absence of autoimmune thyroid disease in the sibship.

Patients and methods

Thirty-five Caucasian sibships with two or more sibs affected by classical or definite rheumatoid arthritis were studied.4 There were 29 pairs, five trios, and one quartet of affected sibs. In two families sib pairs in two generations were considered. Clinical disease features, the presence or absence of other autoimmune diseases, and serum autoantibodies were documented in all patients. Autoantibodies tested for included IgM rheumatoid factor (sheep cell agglutination test (SCAT) by RAHA kit, Fujizoki Inc., Tokyo), antithyroglobulin antibodies by Thymune-T (Wellcome), and antithyroid microsomal antibodies by Thymune-M (Wellcome). The follow-

Accepted for publication 24 July 1985.
Correspondence to Dr D M Grennan, University of Manchester Rheumatic Diseases Centre, Hope Hospital, Salford M6 8HD.
ing titres are found in less than 5% of a local normal population and were considered positive for each test: SCAT 1/32, antithyroglobulin 1/40, antmicrosomal 1/1600. Sibships which included members (either affected or non-affected by RA) either with histories of definite autoimmune thyroid disease (Hashimoto’s disease, primary hypothyroidism with circulating antithyroid autoantibodies, Graves’ disease) or who had significant titres of thyroid autoantibodies on serological testing were categorised as ‘thyroid sibships’ (RA-TH). Haplotype sharing by RA sibling pairs was compared in the thyroid (RA-TH) and non-thyroid (RA-non-TH) sibships.

**Tissue Typing**

HLA-A and B antigens were defined by the standard NIH technique. HLA-DR antigens were defined with B lymphocytes isolated from peripheral blood by their adherence to nylon wool columns. All antisera were obtained locally and were characterised using a cell panel typed with seventh, eighth, and ninth International Histocompatibility antisera.

**Statistical Analysis**

If HLA haplotypes are inherited at random in a particular sibship the probabilities of any sib sharing 0, 1, or 2 haplotypes with a proband are 0.25, 0.5, and 0.25 respectively. The probabilities that the observed frequencies of haplotype sharing differ significantly from the random distribution were analysed by assessing the number of times parental haplotypes were repeated in affected siblings. Values of less than 5% were considered statistically significant.

**Results**

Fifteen sibships contained individuals with clinical or immunological evidence of autoimmune thyroid disease. There were no overall clinical differences in rheumatoid disease severity between members of these ‘thyroid’ sibships and affected members of the other ‘non-thyroid’ sibships. (82% of RA subjects in the ‘thyroid’ and 84% in the ‘non-thyroid’ sibships had received ‘second-line’ drug therapy, and 71% of RA subjects in ‘thyroid’ and 65% in ‘non-thyroid’ sibships had irreversible articular deformities). 69% of RA members in the ‘thyroid’ families and 63% in the ‘non-thyroid’ families were seropositive for rheumatoid factor at the time of assessment. Ten of 15 (67%) probands in the thyroid families and 18 of 20 (90%) in the non-thyroid families were HLA-DR4 positive.

HLA haplotype sharing by RA sibs overall was significantly greater than random (Table 1). The frequencies of HLA haplotype sharing by RA sibs in the ‘thyroid sibships’ (p=0.28) or where the proband was HLA-DR4 negative were not significantly different from the random distribution (Table 1). In both instances where a DR4 negative proband had no haplotypes in common with an affected sibling, that sibling was DR4 positive. There was a trend for greater than random haplotype sharing by six affected sibling pairs where both were DR4 negative (three share one and three share two haplotypes; p=0.097). HLA haplotype sharing by RA sibs after exclusion of the thyroid sibships was highly statistically significant (p=0.006).

**Discussion**

If a single susceptibility gene within the MHC predisposed to both DR4 positive and negative RA, we would expect to find an equivalent and greater than random HLA haplotype sharing by all the categories of RA sibs examined, irrespective of whether the proband was DR4 positive, negative, or belonged to a ‘thyroid’ sibship. The near random haplotype sharing by RA sibs in the latter two categories of sibship as compared with the significantly increased haplotype sharing by RA sibings in the ‘non-thyroid’ sibships suggests that the model of a single RA susceptibility gene linked to the DR locus is incorrect. It seems unlikely that clinical heterogeneity can explain these findings, as overall RA disease severity and frequencies of seropositivity for IgM rheumatoid factor are similar in the ‘thyroid’ and ‘non-thyroid’ sibships. An alternative explanation is that another gene (or genes), not in linkage disequilibrium with HLA-DR4, may also predispose to RA in some DR4 negative or ‘thyroid disease’
families. In these families RA may result from either the gene in linkage disequilibrium with DR4 or the independent gene(s), so that increased HLA haplotype sharing by affected sibs need not occur. We cannot say for certain from the present data whether the genetic effect independent of DR4 is within or outside the MHC. However, although the numbers are small, there is a trend for greater than random haplotype sharing by RA siblings where both or all are DR4 negative, suggesting that the former possibility is more likely.

If there is a second susceptibility gene for RA, we should consider whether this is in linkage disequilibrium with any other DR antigen. An immunogenetic subset of RA has been described which is characterised by circulating antibodies to native type II collagen and which is associated with DR3 and 7.7 This subset is unlikely to account for the present findings, as patients in the subset do not usually give a family history of RA and most of the patients tested here do not have antibodies to type II collagen. An association between RA and HLA-DR1 has been described in Israeli Jews8 and in Indian Asians studied in the UK9 but not in a subsequent study of RA in India.10 HLA-DR3 may act as a marker for high immune responder genes, as suggested by the association between this antigen and high autoantibody titres, immunological side effects of gold and penicillamine, and certain extra-articular disease features of RA.11 We have compared DR antigen frequencies found in a random group of unrelated, DR4 negative, Caucasian, RA patients seen in Greater Manchester with antigen frequencies found in DR4 negative controls (Table 2). Although there is a slight increase in both DR3 and DR1 in the RA group, neither difference is statistically significant. However, there is a statistically significant increase in the combined frequencies of DR1 and DR3 in the RA group, which suggests that the gene independent of DR4 may be in linkage disequilibrium with both DR1 and 3. The increase in DR blanks in the RA group (patients typing for one DR antigen only) could suggest either an increased risk for homozygosity in DR4 negative RA or more probably a role for a DR antigen not yet serologically defined.

The above results suggesting genetic heterogeneity in the pathogenesis of RA are of interest in the light of recent reports that the frequency of the G1m (x) allotype (Gm is coded for by genes on chromosome 1412) is increased in DR4 positive but not DR4 negative RA.1314 Thus the two or more genes within the MHC may interact with different non-HLA linked genes. The second gene within the MHC may also predispose to autoimmune thyroid disease and probably to other autoimmune diseases which occur in relatives of RA probands. Autoimmune thyroid disease may be less frequent in relatives of patients with sporadic RA than in our multicase families.15

Comparison of our observed frequencies for HLA haplotype sharing by affected sibs in 'non-thyroid' families with those expected for different frequencies of a dominant or recessive gene linked to HLA16 suggests that the susceptibility gene in linkage disequilibrium with HLA-DR4 is dominant and has a frequency of about 5%. The frequencies of homozygote and heterozygote genotypes can be calculated from this gene frequency by the Hardy Weinberg formula, and if the prevalence of RA is 2%, these calculations suggest a gene penetrance of around 20%.

We are grateful to the North West Regional Health Authority and to the Arthritis and Rheumatism Council for financial support. We are indebted to the following colleagues from Greater Manchester who have referred some of the families studied or allowed us to see their patients: Dr R Clague, Dr W Dodds, Dr Fallowfield, Dr R Hilton, Professor M I V Jayson, Dr J Marks, Dr J Sharp, Dr P Smith, and Dr D Swinson. The autoantibody tests were carried out by courtesy of Dr M Haeney, Subregional Department of Immunology, Hope Hospital, Salford.

Table 2 Comparison of DR antigen frequencies in DR4 negative RA* patients with those in DR4 negative controls.

(Percentages in parentheses)

<table>
<thead>
<tr>
<th></th>
<th>RA (n=79)</th>
<th>Controls (n=261)</th>
<th>p&lt;sup&gt;+&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>DR1</td>
<td>28 (35-4)</td>
<td>68 (26-1)</td>
<td>0-71</td>
</tr>
<tr>
<td>DR2</td>
<td>16 (20-2)</td>
<td>88 (33-7)</td>
<td>0-15</td>
</tr>
<tr>
<td>DR3</td>
<td>36 (45-6)</td>
<td>90 (34-5)</td>
<td>0-42</td>
</tr>
<tr>
<td>DR5</td>
<td>9 (11-4)</td>
<td>35 (13-4)</td>
<td></td>
</tr>
<tr>
<td>DR6</td>
<td>12 (15-2)</td>
<td>61 (23-4)</td>
<td>0-79</td>
</tr>
<tr>
<td>DR7</td>
<td>17 (21-6)</td>
<td>79 (30-3)</td>
<td>0-095</td>
</tr>
<tr>
<td>DR8</td>
<td>1 (1-2)</td>
<td>12 (4-6)</td>
<td></td>
</tr>
<tr>
<td>DR9</td>
<td>0</td>
<td>4 (1-5)</td>
<td></td>
</tr>
<tr>
<td>DR10</td>
<td>0</td>
<td>2 (0-7)</td>
<td></td>
</tr>
<tr>
<td>Blank</td>
<td>39 (49-4)</td>
<td>83 (31-8)</td>
<td>0-035</td>
</tr>
<tr>
<td>DR1+3</td>
<td>38 (73-4)</td>
<td>147 (56-3)</td>
<td>0-028</td>
</tr>
</tbody>
</table>

*Unrelated British Caucasoids.
†p<sup>+</sup>=probability corrected for the number of comparisons made (Fisher's test).

References

5. Danilovs J A, Ayoub G, Terasaki P I. B lymphocyte isolation...
8 Schiff B, Mizrachi Y, Orgad S, Yaron M, Gazit E. Association of HLA-Aw31 and HLA-Dr1 with adult rheumatoid arthritis. Ann Rheum Dis 1982; 41: 403-4.
HLA haplotype sharing by siblings with rheumatoid arthritis: evidence for genetic heterogeneity.
D M Grennan, P A Sanders, P A Dyer and R Harris

Ann Rheum Dis 1986 45: 126-129
doi: 10.1136/ard.45.2.126